 |
VEVEY, Switzerland, May 22, 2025 /PRNewswire/ -- Nescafé announces today a global partnership with renowned digital magician and filmmaker, Zach King, who will serve as the brand's first-ever global influencer. This exciting collaboration marks a significant step in Nescafé's brand-building strategy to reach a broader and younger audience, bringing coffee into the realm of digital storytelling.
TV Commercial
https://youtu.be/4HBAuI1mvx4
Zach King, the digital wizard
Zach King, from California, USA, has an impressive following of over 185 million fans and holds the Guinness World Record for the most viewed video on TikTok with 2.2 billion views. He ranked number four in the top 10 most watched TikTok videos in 2024. His unique ability to entertain and engage resonates perfectly with Nescafé's vision, particularly among younger consumers aged 18 to 24, through authentic storytelling and innovative content, making him an ideal choice for this collaboration. "I've always loved turning everyday things into something unexpected," said Zach King. "This project with Nescafé has been all about having fun, getting creative, and showing how even your afternoon coffee can have a twist of magic."
Billboard Hack
https://youtube.com/shorts/HsST4ekzBrk
Hacking Nescafé with Zach King
At the heart of this partnership is the new Nescafé Espresso Concentrate, the brand's latest cold coffee range designed for home consumption. This product empowers consumers to craft and personalize their coffee experiences, aligning with the emerging coffee hacking movement. The synergy between Nescafé's expertise and Zach King's creative digital storytelling promises to create a captivating narrative for coffee lovers everywhere.
"Zach King's fan base is young and diverse, mirroring the spirit of our newly launched Nescafé Espresso Concentrate cold coffee," said David Rennie, Executive Vice-President and Head of Strategic Business Units and Marketing and Sales at Nestlé. "We are excited to bring Zach into the Nescafé universe, providing a fantastic platform for our cold coffee hacks. Together, we will create magical moments that resonate with our consumers."
The partnership includes a series of creative digital assets, including TV advertising, exclusive social media videos, and behind-the-scenes content. The partnership will launch first in the US and the UK and will expand globally throughout this year.
Note: the links to the YouTube videos will only become public on the day and time of the announcement
VEVEY, Switzerland, May 22, 2025 /PRNewswire/ -- Nescafé announces today a global partnership with renowned digital magician and filmmaker, Zach King, who will serve as the brand's first-ever global influencer. This exciting collaboration marks a significant step in Nescafé's brand-building strategy to reach a broader and younger audience, bringing coffee into the realm of digital storytelling.
TV Commercial
https://youtu.be/4HBAuI1mvx4
Zach King, the digital wizard
Zach King, from California, USA, has an impressive following of over 185 million fans and holds the Guinness World Record for the most viewed video on TikTok with 2.2 billion views. He ranked number four in the top 10 most watched TikTok videos in 2024. His unique ability to entertain and engage resonates perfectly with Nescafé's vision, particularly among younger consumers aged 18 to 24, through authentic storytelling and innovative content, making him an ideal choice for this collaboration. "I've always loved turning everyday things into something unexpected," said Zach King. "This project with Nescafé has been all about having fun, getting creative, and showing how even your afternoon coffee can have a twist of magic."
Billboard Hack
https://youtube.com/shorts/HsST4ekzBrk
Hacking Nescafé with Zach King
At the heart of this partnership is the new Nescafé Espresso Concentrate, the brand's latest cold coffee range designed for home consumption. This product empowers consumers to craft and personalize their coffee experiences, aligning with the emerging coffee hacking movement. The synergy between Nescafé's expertise and Zach King's creative digital storytelling promises to create a captivating narrative for coffee lovers everywhere.
"Zach King's fan base is young and diverse, mirroring the spirit of our newly launched Nescafé Espresso Concentrate cold coffee," said David Rennie, Executive Vice-President and Head of Strategic Business Units and Marketing and Sales at Nestlé. "We are excited to bring Zach into the Nescafé universe, providing a fantastic platform for our cold coffee hacks. Together, we will create magical moments that resonate with our consumers."
The partnership includes a series of creative digital assets, including TV advertising, exclusive social media videos, and behind-the-scenes content. The partnership will launch first in the US and the UK and will expand globally throughout this year.
Note: the links to the YouTube videos will only become public on the day and time of the announcement
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Nescafé's first-ever global influencer Zach King is bringing magic to the brand
PRINCETON, N.J. and TOKYO, April 1, 2026 /PRNewswire/ -- NJ Bio, Inc. ("NJ Bio"), a leading provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma Services ("Aji Bio‑Pharma"), a leading provider of biopharmaceutical manufacturing services and platform technologies, today announced a research collaboration to expand access to AJICAP™, Aji Bio‑Pharma's site‑specific conjugation platform for NJ Bio's discovery‑stage and early development clients. This collaboration broadens NJ Bio's advanced antibody conjugation and linker capabilities, supporting the development of next‑generation antibody–drug conjugates (ADCs) and other targeted therapeutics.
Through the collaboration, NJ Bio will integrate the AJICAP™ platform into its discovery and development workflows, offering clients a robust and highly reproducible approach for site‑specific conjugation of cytotoxic and non‑cytotoxic payloads to antibodies. AJICAP™ enables precise chemical modification at defined lysine residues without the need for antibody engineering, preserving antibody structure and functionality while improving pharmacokinetics, therapeutic index, and overall developability. The platform supports a range of stable, hydrophilic linker systems and is readily incorporated into drug discovery and development programs.
AJICAP™ technology is widely recognized for its scalability, consistency, and compatibility with standard antibody production processes. By integrating this platform, NJ Bio strengthens its position as a comprehensive partner for biopharmaceutical companies seeking end‑to‑end support, from early drug design and discovery through preclinical development.
Clients will benefit from NJ Bio's deep expertise in medicinal chemistry, bioconjugation, and biologics development, combined with the precision, reproducibility, and flexibility of the AJICAP™ platform. Based on prior technical experience working with AJICAP™ technology, NJ Bio anticipates that this collaboration will help reduce development risk, shorten timelines, and improve overall project outcomes.
"Expanding our capabilities with AJICAP™ aligns strongly with NJ Bio's mission to deliver cutting-edge, high-value solutions that accelerate our clients' discovery programs," said Julien Dugal-Tessier, the President and Chief Scientific Officer at NJ Bio. "This collaboration enables us to offer a proven, scalable site-specific conjugation platform, expand access to AJICAP™ capabilities, and support the development of novel antibody-based medicines with improved efficacy and safety profiles."
"AJICAP™ was developed to enable precise and scalable antibody conjugation, and we are excited to extend its reach through this collaboration with NJ Bio," said Yasuyuki Otake, Corporate Executive, General Manager, Bio-Pharma Services Dept., Ajinomoto Co., Inc. "Together, we are enhancing the tools available to biopharma innovators to design and develop next-generation targeted therapies for patients."
About NJ Bio, Inc.
NJ Bio, Inc. is a leading Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) headquartered in Princeton, New Jersey, with additional chemistry facilities in Bristol, Pennsylvania and Mumbai, India. The company provides fully integrated chemistry and biology services to biotechnology and pharmaceutical companies, supporting programs from early discovery through GMP manufacturing. With deep expertise in bioconjugation, synthetic organic chemistry, protein‑based biopharmaceuticals, and GMP manufacturing, it specializes in ADCs, targeted protein degraders (TPDs), oligo‑conjugates, and other non‑oncology conjugated therapeutics. The organization delivers customized, science‑driven solutions designed to accelerate development timelines and reduce technical risk. NJ Bio has been recognized as "Best Contract Research Organization (CRO)" for multiple consecutive years at the World ADC Conference. Learn more: https://njbio.com/
About Ajinomoto Bio‑Pharma Services
Ajinomoto Bio‑Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, India, Japan, and the United States, providing support across gene therapy, APIs, and both large‑ and small‑molecule manufacturing. The company offers a broad range of innovative platforms and capabilities—from preclinical and pilot programs through commercial supply—including high‑potency APIs (HPAPI), continuous‑flow manufacturing, oligonucleotide synthesis, biocatalysis, CORYNEX® protein expression technology, and antibody–drug conjugation (ADC) services. Learn more: https://ajibio-pharma.ajinomoto.com
For further information, please contact: HERE
Photo - https://mma.prnasia.com/media2/2947092/Bio_Aji_BioPharma_Services_Collaboration.jpg?p=medium600
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development
